Education Qualifications

• Doctor of Philosophy (Pharmaceutical Sciences). Molecular Design of Pharmaceutics – Drug and Gene Delivery. Graduate School of Pharmaceutical Sciences - Hokkaido University – Japan. March, 2006.
• Master of Pharmaceutical Sciences. Molecular Design of Pharmaceutics – Drug and Gene Delivery. Graduate School of Pharmaceutical Sciences - Hokkaido University – Japan. March, 2003.
• Bachelor of Pharmaceutical Sciences. Faculty of Pharmacy – Assiut University - Assiut – Egypt. June, 1997.

Experience

• Professor of Pharmaceutics. RAK Medical and Health Sciences University (Mar 2024~).
• Professor of Pharmaceutics. Assiut University, Egypt (Jul 2020~).
• Assistant Professor. Hokkaido University, Hokkaido, Japan (Sep 2016 to Oct 2019).
• Assistant/Associate Professor. Taibah University, KSA (Oct 2012 to Aug 2016).
• Associate Professor of Pharmaceutics. Assiut University, Egypt (May 2014 to Jun 2020).
• Lecturer of Pharmaceutics. Assiut University, Egypt (Jun 2006 to Apr 2014).

Courses Taught

• Pharmaceutics 1 (Semester 3)
• Pharmaceutics 2 (Semester 4)
• Pharmaceutical Biotechnology 1 (Semester 5)
• Pharmaceutics 4 (Semester 7)
• Pharmaceutical Marketing and Management (Semester 7)
• Biopharmaceutics and Pharmacokinetics (Semester 7)

Publications

(since 2018)

1. M S Ahmed, I A Khalil, K Hassanein, G A El-Gendy, S Ismail. Celecoxib niosomal in-situ gel as a valuable drug delivery system for ocular inflammation. Bulletin of Pharmaceutical Sciences Assiut University, 2023, 46 (2), 757-783.
2. R Shimosakai, I A Khalil, S Kimura, H Harashima. mRNA-loaded lipid nanoparticles targeting immune cells in the spleen for use as cancer vaccines. Pharmaceuticals. MDPI. 2022, 15(8), 1017-.
3. M A Younis, Ikramy A Khalil, Yaser HA Elewa, Yasuhiro Kon, Hideyoshi Harashima. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. Journal of Controlled Release. 2021, 331, 335-349.
4. R Hiradate, I A Khalil, A Matsuda, M Sasaki, K Hida, H Harashima. A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue. Journal of Controlled Release. 2021, 329, 665-675.
5. S Kimura, I A Khalil, Y HA Elewa, H Harashima. Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen. Journal of Controlled Release. 2021, 330, 753-764.
6. Y Hagino, I A. Khalil, S Kimura, K Kusumoto, and H Harashima. GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs. Mol. Pharmaceutics 2021, 18, 3, 878–888.
7. Younis MA, Khalil IA, Harashima H: Gene Therapy for Hepatocellular Carcinoma; Highlighting the Journey from Theory to Clinical Applications. Advanced Therapeutics, 3.11(2020) 2000087.
8. Khalil IA, Harashima H: The GALA peptide: Multiple roles in drug and gene delivery. Bulletin of Pharmaceutical Sciences. Assiut (2020) (accepted manuscript).
9. Khalil IA, Younis MA, Kimura S, Harashima H: Lipid nanoparticles for cell-specific in vivo targeted delivery of nucleic acids. Biol Pharm Bull (2019) (accepted manuscript).
10. Kimura S, Khalil IA (Corresponding author), Elewa YHA, Harashima H: Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization. Journal of controlled release (2019) 313: 70-79.
11. Khalil IA, Sato Y, Harashima H: Recent advances in the targeting of systemically administered non-viral gene delivery systems. Expert opinion on drug delivery (2019) 16: 1037-1050.
12. Younis MA, Khalil IA, Abd Elwakil MM, Harashima H: A Multifunctional Lipid-based Nanodevice for the Highly-specific Co-delivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Mol. Pharmaceutics (2019), 16: 4031-4044.
13. Nakamura T, Yamada Y, Sato Y, Khalil IA, Harashima H: Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials (2019) 119329.
14. Santiwarangkool S, Akita H, Khalil IA, Abd Elwakil MM, Sato Y, Kusumoto K, Harashima H: A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. J Control Release (2019) 307:55-63.
15. Abd Elwakil MM, Khalil IA, Elewa YHA, Kusumoto K, Sato Y, Shobaki N, Kon Y, Harashima H: Lung-endothelium-targeted nanoparticles based on a ph-sensitive lipid and the gala peptide enable robust gene silencing and the regression of metastatic lung cancer. Advanced Functional Materials (2019) 29(18):1807677.
16. Khalil IA, Yamada Y, Harashima H: Optimization of siRNA delivery to target sites: Issues and future directions. Expert Opin Drug Deliv (2018) 1-13.
17. Khalil IA, Kimura S, Sato Y, Harashima H: Synergism between a cell penetrating peptide and a ph-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles. J Control Release (2018) 275:107-116.
18. Khalil IA, Harashima H: An efficient pegylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide. Int J Pharm (2018) 538(1-2):179-187.

Achievements

• Award from the Arab Company for Drug Industries and Medical Appliances (ACDIMA) for the best publication (July 2020). 
• A post-doctor research fellow from Japan Society for the Promotion of Science (JSPS) (Sep 2007 to Sep 2009).
• Nagai Konishi Student Award – From Nagai Foundation – Tokyo – Japan (Sep 2005).
• Best poster for young researchers (2nd) – From the 9th Liposome Research Days (LRD) 2004 – Taiwan (May 2004).